Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
213 Clinical Paid Trials near Austin, TX
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowermRNA Vaccine for Respiratory Syncytial Virus
Austin, Texas
This trial is testing a new vaccine called mRNA-1345 to protect young children and high-risk older children from RSV. The vaccine works by teaching the immune system to recognize and fight the virus. mRNA-1345 is among the most promising RSV vaccines, leveraging the success of mRNA technology seen in COVID-19 vaccines.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:2 - 17
Key Eligibility Criteria
Disqualifiers:Acute Illness, Recent Vaccines, Others
Must Not Be Taking:Immunosuppressants, RSV Antibodies
346 Participants Needed
DB-1311 for Advanced Cancer
Austin, Texas
This trial tests a new drug, DB-1311, in patients with advanced solid tumors. It aims to find the safest and most effective dose and then confirm its safety and effectiveness in more patients.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Heart Failure, Lung Diseases, Infections, Others
Must Not Be Taking:B7-H3 Therapy, Topoisomerase Inhibitors
862 Participants Needed
CAR T Therapy for Multiple Myeloma
Austin, Texas
This trial tests a new therapy using modified immune cells to treat adults with a type of blood cancer that has returned or not responded to treatment. The therapy aims to target and kill cancer cells by recognizing specific proteins on them. This new approach enhances the patient's own immune cells to detect and eliminate cancer cells.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Invasive Malignancy, Cardiac Conditions, CNS Involvement, Others
Must Be Taking:PI, IMiD, AntiCD38
80 Participants Needed
C. difficile Vaccine for C. difficile Infection
Austin, Texas
An antibody is a substance your body makes to fight off infection. This study will explore the safety and antibody response of a vaccine to prevent severe diarrhea caused by a germ called Clostridoides difficile (C. diff). Three new formulations of the C. diff vaccine will be used in this study, in addition to a C. diff vaccine formulation that has been studied in previous clinical trials.
The purpose of this study is to understand if giving the new C. diff vaccine formulations helps people make as many antibodies as giving the previously studied C. diff vaccine formulation.
The study is divided into 2 phases.
Phase 1 will evaluate 3 new formulations of the C. diff vaccine and 2 dosing schedules spread out over 2 months or 6 months.
The Phase 1 portion of the study is seeking participants:
* who are healthy adults of 65 to 84 years of age
* who have not had a C. diff infection before
* who have not received a C. diff vaccine or C. diff monoclonal antibody therapy before.
All participants in Phase 1 will receive study injections with active vaccine or placebo at each vaccination visit, depending on the vaccine group to which they are assigned. A placebo does not contain any active ingredients. Participants in Phase 1 will attend at least 9 study visits and will take part in the study for approximately 18 months. Based on the results of Phase 1, 1 or 2 of the new C. diff vaccine formulations will be chosen for further study in Phase 2.
Phase 2 will evaluate the safety and effects of the new C. diff vaccine formulation(s) chosen in Phase 1.
The Phase 2 portion of the study is seeking participants:
* who are healthy adults ≥65 years of age
* who have not had a C. diff infection before
* who have not received a C. diff vaccine or C. diff monoclonal antibody therapy before.
Phase 2 participants will receive active C. diff vaccine or placebo at each vaccination visit. Participants in Phase 2 will attend at least 6 and up to 12 study visits and will take part in the study for up to 4 years.
A booster stage for selected participants in Phase 2 will have participants receive active C. diff vaccine or placebo to examine immune persistence. The booster stage participants will attend at least 10 additional study visits and will take part in the study for 6 years.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:65 - 84
Key Eligibility Criteria
Disqualifiers:Chronic Disorders, Immunodeficiency, C. Diff History, Others
Must Not Be Taking:Anticoagulants, Immunosuppressants
779 Participants Needed
AR-14034 for Age-Related Macular Degeneration
Austin, Texas
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+
Key Eligibility Criteria
Disqualifiers:Ocular Disease, Glaucoma, Hypertension, Others
Must Be Taking:Ocular Anti-VEGF
140 Participants Needed
ALN-KHK for Type 2 Diabetes
Austin, Texas
This trial is testing a new drug called ALN-KHK to see how safe it is and how the body processes it. They are also testing another drug called KHK to check its safety and effectiveness. The study targets patients who might benefit from these drugs, aiming to understand their safety and how they work in the body.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Not Listed
49 Participants Needed
BMF-219 for Type 2 Diabetes
Austin, Texas
This trial tests a new pill called BMF-219 that targets a protein named menin. It includes healthy adults and those with Type 2 Diabetes to see if it helps control blood sugar levels.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Not Listed
414 Participants Needed
Bone Marrow Transplant for Leukemia
Austin, Texas
This trial is testing the safety of using bone marrow from a deceased donor to treat patients with severe leukemia. The goal is to see if this new bone marrow can help produce healthy blood cells. Patients will be monitored closely for any side effects and overall effectiveness over several months.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Living Donor, Prior HCT, Pregnancy, Infections, Others
Must Not Be Taking:Investigational Drugs
12 Participants Needed
PRO1184 for Cancer
Austin, Texas
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.
Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Interstitial Lung Disease, Others
Must Be Taking:Platinum-based Chemotherapy
569 Participants Needed
Monoclonal Antibody Therapy for Cancer
Austin, Texas
This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas.
The main goals of this study are to:
* Find the recommended dose of IMT-009 that can be safely given to participants
* Learn more about the side effects of IMT-009
* Learn more about pharmacokinetics of IMT-009
* Learn more about the effectiveness of IMT-009
* Learn more about different pharmacokinetic biomarkers and how they might change in the presence of IMT-009
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Autoimmune Disease, HIV, Others
Must Not Be Taking:Investigational Drugs, CYP3A4 Modulators
67 Participants Needed
CAR-T Therapy for Non-Hodgkin's Lymphoma
Austin, Texas
This trial tests a new treatment where a patient's own immune cells are modified to better attack their cancer. It is for adults with a type of lymphoma that hasn't responded to other treatments. The modified cells target specific proteins on the cancer cells to help the immune system destroy them. This new method enhances the patient's immune cells to find and eliminate cancer cells.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Organ Transplant, Stroke, Heart Failure, Others
Must Be Taking:Anti-CD20 Antibody
385 Participants Needed
RMC-6236 for Cancer
Austin, Texas
This trial is testing a new drug called RMC-6236, which is taken by mouth and targets a protein called RAS. It is aimed at adults with advanced cancers that have specific mutations in the RAS protein. The drug works by blocking this protein, which helps stop the cancer cells from growing.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:CNS Tumors, Brain Metastases, GI Impairment, Others
754 Participants Needed
Erdafitinib Delivery System for Bladder Cancer
Austin, Texas
This trial tests a new way to deliver a drug called Erdafitinib directly into the bladder for patients with certain types of bladder cancer. These patients have genetic changes that make their cancer harder to treat. The drug works by blocking proteins that help the cancer grow. The goal is to find the best dose and see how well it works and how safe it is.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Concurrent Extra-vesical Carcinoma, Others
Must Not Be Taking:FGFR Inhibitors
262 Participants Needed
CRV-101 Vaccine for Shingles
Austin, Texas
This trial tests a new shingles vaccine called CRV-101 in adults aged 50 and older. The vaccine aims to boost the immune system to prevent shingles. Participants receive two injections and are monitored for safety and effectiveness.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50+
Key Eligibility Criteria
Disqualifiers:Herpes Zoster, Autoimmune Disease, Others
Must Not Be Taking:Immunosuppressants, Cytotoxic Therapies
1516 Participants Needed
IPG7236 for Advanced Cancer
Austin, Texas
This trial tests a new drug, IPG7236, in patients with advanced solid tumors to see if it is safe and can help shrink their tumors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:CNS Malignancy, HIV-related Cancer, Others
Must Not Be Taking:QT Prolonging Drugs
196 Participants Needed
MenABCWY Vaccine for Meningococcal Meningitis
Austin, Texas
This trial is testing a new vaccine that protects against five types of bacteria causing serious infections. It targets people at risk of these infections and works by helping their immune system recognize and fight the bacteria.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:11 - 14
Key Eligibility Criteria
Disqualifiers:Neuroinflammatory, Autoimmune, Immunodeficiency, Others
Must Not Be Taking:Corticosteroids, Antineoplastics, Immunomodulators, Others
302 Participants Needed
NGM707 + Pembrolizumab for Cancer
Dallas, Texas
This trial is testing a new drug called NGM707, both by itself and with another drug, Pembrolizumab. It targets patients with very advanced or spreading solid tumors. The treatment aims to boost the immune system to better fight cancer.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Others
Must Not Be Taking:ILT2, ILT4, HLA-G
179 Participants Needed
EG-70 for Bladder Cancer
Austin, Texas
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC.
This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is.
The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or inadequately treated.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Recent Malignancy, Renal Failure, Metastatic Disease, Others
Must Not Be Taking:Chemotherapy, Pembrolizumab
350 Participants Needed
PC14586 for Solid Tumors
Austin, Texas
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12+
Key Eligibility Criteria
Disqualifiers:Primary CNS Tumor, Heart Conditions, Active Infection, Others
Must Not Be Taking:Strong CYP3A4 Inducers
300 Participants Needed
Zifibancimig for Age-Related Macular Degeneration
Austin, Texas
This trial is testing a new treatment called zifibancimig for people with a serious eye condition known as neovascular age-related macular degeneration (nAMD). The treatment is given either as an injection into the eye or through a small implant. It works by stopping harmful blood vessels from growing in the eye, which can help protect or improve vision.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+
Key Eligibility Criteria
Disqualifiers:Vitrectomy, Glaucoma, Uveitis, Others
Must Be Taking:Anti-VEGF
251 Participants Needed
Why Other Patients Applied
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
AGN-193408 SR for Glaucoma
Austin, Texas
This trial is testing a new medication called AGN-193408 SR to see if it can safely lower eye pressure in people with open-angle glaucoma or ocular hypertension.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Ocular Trauma, Herpetic Ocular Diseases, Others
Must Not Be Taking:Corticosteroids
96 Participants Needed
UCART22 for Acute Lymphoblastic Leukemia
Austin, Texas
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and clinical activity of UCART22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:15 - 50
Key Eligibility Criteria
Disqualifiers:Prior Cellular Therapy, Others
52 Participants Needed
MRTX849 for Cancer
Austin, Texas
This trial is testing a new pill called MRTX849 (adagrasib) for patients with advanced cancers that have a specific genetic change called KRAS G12C. The pill aims to block this change and stop the cancer from growing. Adagrasib is similar to another approved treatment and is intended for patients with this genetic change who have already received other treatments.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Intestinal Disease, Major Gastric Surgery, Other Active Cancer
731 Participants Needed
Sotorasib for Solid Tumors
Austin, Texas
Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors.
Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Active Brain Metastases, Recent Myocardial Infarction, GI Tract Disease
713 Participants Needed
Favezelimab + Pembrolizumab for Lymphoma
Austin, Texas
This study will evaluate the safety and efficacy of favezelimab (MK-4280) in combination with pembrolizumab (MK-3475) using a non-randomized study design in participants with the following hematological malignancies:
* classical Hodgkin lymphoma (cHL)
* diffuse large B-cell lymphoma (DLBCL)
* indolent non-Hodgkin lymphoma (iNHL)
This study will also evaluate the safety and efficacy of pembrolizumab or favezelimab administered as monotherapy in participants with cHL using a 1:1 randomized study design.
The study will have 2 phases: a safety lead-in and an efficacy expansion phase. The recommended Phase 2 dose (RP2D) will be determined in the safety lead-in phase by evaluating dose-limiting toxicities.
There is no primary hypothesis for this study.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:CNS Involvement, Autoimmune Disease, Others
Must Not Be Taking:Steroids, Immunosuppressants, Others
174 Participants Needed
Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Immunodeficiency, Others
Must Not Be Taking:PD-1 Inhibitors, Idelalisib
52 Participants Needed
BMS-986253 + Immunotherapy for Advanced Cancer
Austin, Texas
This trial is testing a new drug called BMS-986253 along with other cancer treatments, Nivolumab and Ipilimumab, in patients with advanced cancers to see if it can improve their effectiveness.
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Autoimmune Disease, HIV/AIDS, Others
Must Not Be Taking:Corticosteroids, Immunosuppressives, Cytotoxic Agents
281 Participants Needed
Itacitinib + Osimertinib for Lung Cancer
Austin, Texas
This trial is testing the safety of using two drugs, itacitinib and osimertinib, together. The study focuses on patients with advanced lung cancer that has spread. Itacitinib helps the immune system fight cancer, while osimertinib targets and kills specific cancer cells. Osimertinib is approved for treating a specific type of lung cancer, even in cases where the cancer has become resistant to other treatments.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Cardiac Disease, ILD, Others
Must Be Taking:EGFR TKI
59 Participants Needed
Acalabrutinib + ACP-319 for B-cell Cancers
Austin, Texas
This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy acalabrutinib and ACP 319 in B-cell malignancies.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:CNS Involvement, Low ANC, Others
Must Not Be Taking:Therapeutic Antibodies
40 Participants Needed
Combination Vaccine for Flu and COVID-19
Austin, Texas
This study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine. The flu portion will target multiple strains of the flu virus, while the COVID-19 part will focus on the spike protein of the SARS-CoV-2 virus. Both parts of this vaccine have been tested individually before. This will be the first study to test the combined vaccine in humans in healthy adult participants.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 64
Key Eligibility Criteria
Disqualifiers:Pregnancy, Immunodeficiency, Cancer, Others
Must Not Be Taking:Immune-modifying Drugs, Others
107 Participants Needed
Know someone looking for new options?
Spread the word